Issue 148 | November 2024
Cell and gene therapy approvals drive paradigm change in manufacturing
In this issue: The manufacturing shift to meet growing cell and gene therapy (CGT) demand, applying lessons from the Covid-19 pandemic to address mpox, Opdivo and Keytruda, a ten-year review, and more.